ArticleDermatology and therapy2026

EP262, an MRGPRX2 Antagonist for the Treatment of Atopic Dermatitis: Results From the Phase 2 Randomized EASE Study.

Shirley Dehn et al.PubMed ↗Publisher ↗

No numbers read from the abstract.